Invitae study reports universal genetic testing improves outcomes for patients with breast cancer–
SAN FRANCISCO, Sept. 22, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, released a new study inJAMA Network Open, underscoring the clinical utility of the American Society of Breast Surgeons (ASBrS) guidelines recommending universal genetic testing for patients with breast cancer, and showing universal testing improves patient outcomes. Building on a previous study reported in theJournal of Clinical Oncology, the current study is the first clinical outcomes study of a cohort of unselected patients with breast cancer who underwent universal germline genetic testing. Our data...